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Background: The Global Burden of Disease (GBD) 2010 Study has published disability-adjusted life year (DALY) data
at both regional and country levels from 1990 to 2010. Concurrently, the Institute for Health Metrics and Evaluation
(IHME) has published estimates of development assistance for health (DAH) at the country-disease level for this
same period of time.
Findings: We use disease burden data from the GBD 2010 study and financing data from IHME to calculate
ratios of DAH to DALYs across regions and diseases. We examine the magnitude of these ratios and how they
have varied over time. We hypothesize that the variation in this ratio across regions would be relatively small.
However, from 2006 to 2010, we find there was considerable variation in the levels of DAH per DALY across
regions. For total funding, the relative standard deviation (standard deviation as a percentage of the mean)
across regions was 50%. For DAH specific to HIV/AIDS, malaria and tuberculosis, the relative standard deviations
were 50%, 200% and 60%, respectively. While these deviations are high, with the exception of malaria, they have
decreased since the 1990s.
Conclusions: There are no evident explanations for so much variation in funding across regions, especially
holding the purpose of the funding constant. This suggests donors’ allocation processes have not been
particularly sensitive to disease burdens. To maximize health gains, donors should explicitly incorporate
new disease burden data along with the relative costs and efficacy of interventions into their allocation
process.
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There is remarkable variation in the level of develop-
ment assistance for health (DAH) per disability adjusted
life-year (DALY) across regions and diseases. From 2006
to 2010, the rate of total DAH per all-cause DALY
ranged from $16 to $78 across regions (all financial
values in 2010 US dollars). The regional variation in
disease-specific funding was generally more extreme.
DAH per DALY ranged from $174 to $749 for HIV/
AIDS, $62 to $36,030 for malaria and $38 to $305 for
tuberculosis (TB). Some variation across diseases may
be justified by differences in the relative costs and* Correspondence: hanlonm@uw.edu
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reproduction in any medium, provided the orefficaciousness of interventions. Yet little evidence ex-
ists to explain the massive variation in disease-specific
funding that we observe across regions.Methods
DAH is comprised of funds that originate in developed
countries and are disbursed to developing countries
with the stated purpose of improving population health.
DAH estimates were obtained from the Financing Global
Health series produced by the Institute for Health Metrics
and Evaluation (IHME) [1-4]. To generate the 2012
report, IHME collected data from entities that contrib-
uted to DAH from 1990 to 2012. Annual reports, pub-
licly available data, and information acquired via
correspondence feed into the DAH dataset. Some dataLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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organizations. We used the publicly-available dataset
from the 2012 report to generate disbursement amounts
through 2010, which is the most recent year for which
disease-specific estimates are available [4]. In 2010, 79%
of total DAH could be tracked to a specific focus area,
such as HIV/AIDS, malaria or TB. Insufficient data exist
on the remaining 21% to comment on its allocation across
diseases or regions, but this “unallocable” fraction has
decreased steadily in recent years as larger donors have
embraced the practice of publicly sharing project-level
data.
Disease burden is measured by a country’s number of
DALYs. This metric combines the number of years of
life lost due to premature mortality and the years lived
with disability. It simultaneously accounts for condi-
tions which result in mortality and those which result
in disability. The metric was specifically developed to as-
sess the burden of disease [5] and it has been adopted by
the World Health Organization as its preferred metric for
quantifying burden [6]. Total DALYs are calculated by
summing disease-specific DALYs, such as those directlyFigure 1 Total DAH per DALY, by region.attributable to HIV/AIDS, malaria and TB, among many
other conditions. For further description, see The Lancet’s
issue devoted to the Global Burden of Disease (GBD)
2010 Study [7-9].
The GBD 2010 Study produced DALY estimates for
five points in time: 1990, 1995, 2000, 2005 and 2010.
To pair DALYs with DAH, we sum DAH in a five-year
interval such that the final year of each interval
matches a DALY estimate. We sum DAH and DALYs
at the regional level, with regions defined by the World
Bank. We calculate regional-level ratios of DAH to
DALYs. These ratios are used to generate a relative
standard deviation (RSD), which is the coefficient of
variation expressed as a percentage (the ratio of the
standard deviation to the mean, times one hundred).
RSDs are calculated for total DAH and all-cause
DALYs, as well as those specific to HIV/AIDS, malaria
and TB.
Results
Figure 1 illustrates that DALYs have been flat or de-
creasing over time while levels of DAH have increased
Figure 2 Global map of DAH per DALY at the country level, 2006 – 2010. DAH was aggregated at the country level from 2006 to 2010 and
compared to country-level DALYs reported in the year 2010.
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of DAH to DALYs increased in all regions of the world
over the past two decades. In addition to the temporal
variation, there is considerable variation in the ratio
across regions. South Asia, East Asia and the Pacific re-
ceive relatively little DAH per DALY, while Sub-Saharan
Africa receives the most. Figure 2 illustrates DAH per
DALY at the country level. It highlights country-levelFigure 3 Global DAH per DALY, by disease.variation exists within regions. Figure 3 illustrates the
variation across disease-specific funding. It highlights
that donors provide much more DAH per HIV DALY
than from other burdens.
Figures 4, 5 and 6 illustrate regional levels of DAH
per DALY for HIV/AIDS, malaria and TB, respectively.
For HIV/AIDS, the Middle East and Latin America
receive high levels of funding relative to the burden.
Figure 4 HIV/AIDS DAH per HIV/AIDS DALY, by region.
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For malaria, extremely high levels are allocated to
Europe and Central Asia, in large part because of the
relatively low burden in that region. For TB, high levels
are allocated to Europe and Central Asia and Latin
America, while low levels are allocated to Sub-Saharan
Africa and South Asia. Table 1 reports the RSD in funding
over time. While large variations exist from 2006 to 2010,
in general the level of variation has actually decreased over
time. The notable exception is funding for malaria, in
which the variation continues to increase because of in-
creasingly large allocations of DAH to countries in Europe
and Central Asia.
Discussion
A large literature examines how factors such as per capita
income, population levels and measures of governanceFigure 5 Malaria DAH per malaria DALY, by region.affect foreign aid allocations [10-24]. Some of this lit-
erature explicitly focuses on disease burden [23,24].
The practicality of this literature is limited because many
studies focus on the associations between variables, rather
than causal pathways. Regardless, to our knowledge no
study has focused on the ratio of assistance to burden. We
believe this is a useful metric that should influence donor
behavior.
We find massive variation in this ratio, which sug-
gests donors have not been sensitive to disease burdens
in making their allocations. This finding may be some-
what expected, for four reasons. First, some large do-
nors like the Global Fund have employed allocation
mechanisms in which grants are functions of many fac-
tors in addition to burden [25]. Second, some organi-
zations may avoid allocating aid based on burden
averted to avoid the perverse dynamic of punishing
Figure 6 TB DAH per TB DALY, by region.
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specific disease. Third, for some donors, the true pur-
pose of health aid may extend beyond improving popu-
lation health. Finally, historically data on burden have
not been readily accessible. Even if donors wanted to
focus on burden, it was in some cases operationally
impractical.
Variation in all-cause funding across regions is in
part due to donors’ demand to target funding to several
high-profile diseases, as illustrated in Figure 3. For ex-
ample, populations in Sub-Saharan Africa suffer dis-
proportionately from HIV/AIDS. As donors prioritize
that disease, countries in Sub-Saharan Africa will re-
ceive disproportionately large allocations of DAH, which
serves to increase the variation in DAH to DALYs across
countries. The variation across diseases may in part
be justified by differences in the relative costs and ef-
fectiveness of disease-specific interventions. However,
given the current evidence about costs and effective-
ness, it is unclear that those factors alone could explain
the observed differences. The variation across regions for
a given type of funding, illustrated in Figures 4 5 and 6, is
a more surprising and somewhat inexplicable result. LatinTable 1 Relative standard deviations in funding across
regions over time
Time period Funding area
Total HIV/AIDS Malaria TB
1991 – 1995 58% 124% 145% 125%
1996 – 2000 86% 72% 179% 105%
2001 – 2005 68% 65% 170% 84%
2006 – 2010 53% 45% 203% 64%America and the Caribbean receive consistently high
allocations across diseases, while South Asia’s allocations
are consistently low. However, other region-disease com-
binations are highly idiosyncratic.
As donors allocate capital in the future, and in some
cases reconsider their allocation strategies, we believe
three policy issues are relevant to address. First, to what
degree does population health matter in the allocation of
health aid? Second, to the degree that burden influences
the allocation, are donors using consistent measures of
burden across diseases? Third, holding the decision to
address burden from a specific cause, are the alloca-
tions equitable across regions? DALYs from the Global
Burden of Disease 2010 Study are a useful tool to address
the second and third issues. This data could serve as a
useful input to donors’ allocation processes and reduce
variations in the future.Competing interests
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